NCT00117988View on ClinicalTrials.gov

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Anaplastic Large Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Mantle Cell Lymphoma
Interventions
DRUG

tanespimycin

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00117988 - 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter